Does Priority Health Cover Mounjaro?
The verdict
Conditional on most plans
Priority Health (Michigan) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, Medicare Part D, and MI Medicaid lines. Mounjaro is not covered for weight loss. Michigan Medicaid covers weight-loss GLP-1s — but that applies to the on-label products Wegovy and Zepbound, not Mounjaro, which is diabetes-only. The weight-loss tirzepatide is Zepbound, with separate coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Priority Health using your member ID.
Key facts
Michigan Medicaid covers weight-loss GLP-1s for the on-label weight-loss products (Wegovy, Zepbound) — but not for Mounjaro, which is FDA-approved for type 2 diabetes only. Mounjaro is covered under MI Medicaid for T2D with PA.
Michigan Department of Health and Human Services, Medicaid Preferred Drug List, 2025–2026
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Priority Health Part D enrollees on Mounjaro for T2D reach this cap within 2–3 months and pay $0 for the remainder of the year.
CMS.gov, Medicare Part D Redesign 2025–2026
The IRA-negotiated Medicare MFN price for tirzepatide (Mounjaro) is $245/month, effective mid-2026 for Medicare enrollees.
CMS.gov, IRA Drug Price Negotiation Program, 2026
Medicare vs. commercial coverage
Whether Priority Health covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Priority Health Medicare Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027), which covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). The Lilly savings card is not usable by Medicare beneficiaries. Verify on the Priority Health Medicare formulary.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Priority Health commercial plans cover Mounjaro for T2D with prior authorization. Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s are commonly excluded on commercial plans. MI Medicaid: Michigan Medicaid covers weight-loss GLP-1s for the on-label products (Wegovy, Zepbound) — that coverage does not extend to Mounjaro, which is diabetes-only and covered for T2D with PA at nominal cost-share. The Lilly savings card is not available to Medicaid beneficiaries. Verify tier and copay on the Priority Health formulary or member services.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured patients without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: plan-specific cost-share — verify on Priority Health formulary. Lilly savings card: as low as $25/month for commercially insured patients with coverage. Medicare Part D: 25% coinsurance after deductible to the $2,100 OOP cap 2026; MFN $245/month mid-2026. MI Medicaid: nominal cost-share with PA.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by Priority Health product and pharmacy. Confirm tier and copay on the Priority Health formulary or by calling member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Mounjaro on the Priority Health formulary
Visit priorityhealth.com or your member portal and use the plan drug list (formulary) for your specific product (commercial, ACA, or Medicare Part D). Search for 'Mounjaro' or 'tirzepatide'. Confirm it is listed for type 2 diabetes (E11.x), note the tier, and check whether prior authorization is required. MI Medicaid members should confirm T2D coverage and PA requirements with Michigan Medicaid or Priority Health member services.
- 2
Have your prescriber submit the prior authorization
Your prescriber must document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior oral agent step therapy (metformin plus typically one additional agent). Ask your prescriber's office to submit a PA request to Priority Health. Verify the specific PA criteria on the Priority Health formulary before submission.
- 3
Call Priority Health member services to confirm coverage and MI Medicaid status
Call the number on the back of your Priority Health card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my cost-share after prior authorization? Does MI Medicaid's weight-loss GLP-1 coverage apply to Mounjaro? (Answer: No — MI Medicaid covers weight-loss GLP-1s for Wegovy and Zepbound; Mounjaro is covered for T2D only.)
Options if Priority Health won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Often covered with PA on Priority Health commercial and Medicare Part D plans; may be at a more favorable tier than Mounjaro — verify on plan formulary.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative with lower list price; often preferred tier on Michigan commercial and Medicaid formularies — verify on Priority Health plan.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. Often preferred tier; may be required as step therapy before GLP-1 approval. Verify on Priority Health formulary.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. MI Medicaid covers weight-loss GLP-1s for on-label products including Zepbound — verify current MI Medicaid PDL status. Has separate coverage from Mounjaro. Do not substitute Mounjaro for Zepbound — they are different FDA approvals.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Mounjaro is FDA-approved for type 2 diabetes only — not weight loss. Priority Health does not cover Mounjaro for off-label weight loss under any line. The weight-loss tirzepatide is Zepbound, which has separate coverage. Even though Michigan Medicaid covers weight-loss GLP-1s, that applies to the on-label products Wegovy and Zepbound, not Mounjaro.
No. Michigan Medicaid covers weight-loss GLP-1s for the on-label weight-loss products — Wegovy and Zepbound. That coverage does not extend to Mounjaro, which is FDA-approved for type 2 diabetes only. Mounjaro is covered under Priority Health MI Medicaid for T2D with prior authorization, at nominal cost-share. If weight loss is your goal, Zepbound is the applicable product — verify its MI Medicaid status separately.
Priority Health and BCBS Michigan both operate in Michigan where MI Medicaid covers weight-loss GLP-1s. The key commercial difference: BCBS Michigan had its Zepbound weight-loss exclusion upheld by the Michigan DIFS in 2025, making it one of the few commercial plans with a formally litigated weight-loss GLP-1 exclusion. Priority Health follows a more standard commercial pattern — verify its Zepbound and Mounjaro coverage separately on the Priority Health formulary.
Commercial cost-share varies — verify on the Priority Health formulary. The Lilly savings card can reduce cost to as little as $25/month for commercially insured patients with coverage, or $499/month without (expires 12/31/2026; excludes Medicare and Medicaid). Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026. MI Medicaid: nominal cost-share with PA.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only: Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Priority Health Medicare Part D covers Mounjaro for diabetes under standard Part D with prior authorization and the $2,100 annual OOP cap.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Oscar Health Cover Mounjaro? ACA & T2D Guide 2026 | Curex
Oscar covers Mounjaro for type 2 diabetes with prior auth — not weight loss. ACA plans exclude weight-loss GLP-1s; Zepbound is the weight-loss tirzepatide.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Priority Health covers Mounjaro for diabetes only — even where MI Medicaid covers weight-loss GLP-1s, that applies to Zepbound and Wegovy, not Mounjaro. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Priority Health before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.